Rifampicin Production Costs - Q2 2023
Rifampicin Operating Costs & Plants Capital Investment
Rifampicin (a.k.a. Rifampin) iis a macrocyclic antibiotic with strong activity against gram-positive bacteria and gram-negative cocci, mycobacteria, commonly used in combination with other agents as therapy of tuberculosis, leprosy, and legionella. Rifampicin is produced by the microorganism Streptomyces mediterranei.
Intratec offers professional, easy-to-understand reports examining Rifampicin production costs. Each study describes an industrial plant, including main process units and site infrastructure, and presents an independent analysis of capital and operating costs. All reports are based on the most recent economic data available (Q2 2023).
Rifampicin Production
This report presents the economics of Rifampicin production from mixed carbon sources (peanut meal, soybean flour, glucose, and starch) in the United States, via a typical fermentation process of Nocardi mediterranei. The fermentation produces rifamycin B, which is further processed in many steps until Rifampicin is obtained.
Details: 0.10 kta United States-based plant | Q2 2023 | 107 pages From $1,999 USD
The cost analyses presented in the report Rifampicin E11A target a 0.10 kta (kilometric tons per annum) United States-based plant. For those interested in cost analyses considering other plant capacities and/or locations, Intratec offers a customized analysis as an optional feature.
Could Not Find the Production Cost Report you Need?
If none of the Rifampicin reports listed above fits your needs, you can request a bespoke report examining the process you are interested in! You will have a report tailored to your needs, in which you defined production process, industrial plant capacity and location!
Details: Customer-defined Plant Location & Capacity | Q2 2023 From $2,900 USD
Customers Who Bought This Report Also Bought
Amoxicillin Production
This report presents the economics of Amoxicillin Trihydrate production from D(-)p-hydroxyphenylglycine and 6-APA in the United States. The process examined is a conventional chemical synthesis (via the Dane salt route).
Details: 0.40 kta United States-based plant | Q2 2023 | 108 pages From $1,999 USD
The cost analyses presented in the report Amoxicillin E11A target a 0.40 kta (kilometric tons per annum) United States-based plant. For those interested in cost analyses considering other plant capacities and/or locations, Intratec offers a customized analysis as an optional feature.
Bronopol Production
This report presents the economics of a typical Bronopol production process from sodium hydroxide, calcium chloride, nitromethane, and liquid bromine in the United States.
Details: 100 kta United States-based plant | Q2 2023 | 107 pages From $1,999 USD
The cost analyses presented in the report Bronopol E11A target a 100 kta (kilometric tons per annum) United States-based plant. For those interested in cost analyses considering other plant capacities and/or locations, Intratec offers a customized analysis as an optional feature.
Pyrantel Pamoate Production
This report presents the economics of Pyrantel Pamoate production from 2-thiophene aldehyde in the United States. 3-Methylamine propylamine is first sent to a cyclization step before it is reacted with 2-thiophene aldehyde. Ethanol and citric acid are added to the reaction product, followed by the addition of a pamoic acid solution for recrystallization, obtaining pyrantel pamoate.
Details: 0.10 kta United States-based plant | Q2 2023 | 107 pages From $1,999 USD
The cost analyses presented in the report Pyrantel Pamoate E11A target a 0.10 kta (kilometric tons per annum) United States-based plant. For those interested in cost analyses considering other plant capacities and/or locations, Intratec offers a customized analysis as an optional feature.
Use our Reports as
Feasibility Studies
Techno-economic Evaluations
Investment Analyses
Multi-regional Cost Analyses
Trusted By
